Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial
The Lancet Neurology, 05/07/2012Walter S et al.
For patients with suspected stroke, treatment by the mobile stroke unit (MSU) substantially reduced median time from alarm to therapy decision. The MSU strategy offers a potential solution to the medical problem of the arrival of most stroke patients at the hospital too late for treatment.
The authors did a randomised single-centre controlled trial to compare the time from alarm (emergency call) to therapy decision between mobile stroke unit (MSU) and hospital intervention.
For inclusion in the study patients needed to be aged 18-80 years and have one or more stroke symptoms that started within the previous 2.5 h.
In accordance with the week-wise randomisation plan, patients received either prehospital stroke treatment in a specialised ambulance (equipped with a CT scanner, point-of-care laboratory, and telemedicine connection) or optimised conventional hospital-based stroke treatment (control group) with a 7 day follow-up.
Allocation was not masked from patients and investigators.
The primary endpoint was time from alarm to therapy decision, which was analysed with the Mann-Whitney U test.
The secondary endpoints included times from alarm to end of CT and to end of laboratory analysis, number of patients receiving intravenous thrombolysis, time from alarm to intravenous thrombolysis, and neurological outcome.
They also assessed safety endpoints.
They stopped the trial after the planned interim analysis at 100 of 200 planned patients (53 in the prehospital stroke treatment group, 47 in the control group), because they had met the prespecified criteria for study termination.
Prehospital stroke treatment reduced the median time from alarm to therapy decision substantially: 35 min (IQR 31-39) versus 76 min (63-94), p<0.•0001; median difference 41 min (95% CI 36-48 min).
They also detected similar gains regarding times from alarm to end of CT, and alarm to end of laboratory analysis, and to intravenous thrombolysis for eligible ischaemic stroke patients, although there was no substantial difference in number of patients who received intravenous thrombolysis or in neurological outcome.
Safety endpoints seemed similar across the groups.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.